Abstract
Due to the presence of the blood-brain barrier, there is limited drug access into the brain. In order to overcome this challenge, various strategies have been developed to enhance penetration of drugs into the brain. Of these, the most frequently used are pharmacological technologies or comparable methods being developed for brain-targeting drug delivery using receptor- or adsorptive- or transporter-mediated transcytosis and the nose-to-brain route. It goes without saying that exploration of Brain-targeting drug delivery systems has created another potential option for the treatment of central nervous system diseases. In addition to above methods, other technologies for brain-targeting drug delivery (e.g. chemical delivery systems, prodrugs, pharmacological disruption of the BBB and inhibition of drug efflux by P-glycoprotein) are also summaried in this review.
Keywords: Blood-brain barrier, brain-targeting drug delivery systems, receptor-mediated transcytosis, adsorptive-mediated transcytosis, transporter-mediated transcytosis, nose-to-brain, chemical delivery systems, prodrugs, P-glycoprotein, Targeting drug delivery, colloidal drug, harmful blood-borne substances, small molecule drugs, endothelium cells
Current Pharmaceutical Biotechnology
Title:Perspectives on Brain-Targeting Drug Delivery Systems
Volume: 13 Issue: 12
Author(s): Liangran Guo, Jinfeng Ren and Xinguo Jiang
Affiliation:
Keywords: Blood-brain barrier, brain-targeting drug delivery systems, receptor-mediated transcytosis, adsorptive-mediated transcytosis, transporter-mediated transcytosis, nose-to-brain, chemical delivery systems, prodrugs, P-glycoprotein, Targeting drug delivery, colloidal drug, harmful blood-borne substances, small molecule drugs, endothelium cells
Abstract: Due to the presence of the blood-brain barrier, there is limited drug access into the brain. In order to overcome this challenge, various strategies have been developed to enhance penetration of drugs into the brain. Of these, the most frequently used are pharmacological technologies or comparable methods being developed for brain-targeting drug delivery using receptor- or adsorptive- or transporter-mediated transcytosis and the nose-to-brain route. It goes without saying that exploration of Brain-targeting drug delivery systems has created another potential option for the treatment of central nervous system diseases. In addition to above methods, other technologies for brain-targeting drug delivery (e.g. chemical delivery systems, prodrugs, pharmacological disruption of the BBB and inhibition of drug efflux by P-glycoprotein) are also summaried in this review.
Export Options
About this article
Cite this article as:
Guo Liangran, Ren Jinfeng and Jiang Xinguo, Perspectives on Brain-Targeting Drug Delivery Systems, Current Pharmaceutical Biotechnology 2012; 13 (12) . https://dx.doi.org/10.2174/138920112803341770
DOI https://dx.doi.org/10.2174/138920112803341770 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Insight into the Inflammatory and Cellular Responses Following Experimental Glaucoma Surgery: A Roadmap for Inhibiting Fibrosis
Current Molecular Medicine New Drugs for Epidural Analgesia
Current Drug Targets Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Healthy Properties of Garlic
Current Nutrition & Food Science Pediatric Chronic Daily Headache
Current Pediatric Reviews The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis
Current Vascular Pharmacology Biological Rationale for Regular Physical Exercise as an Effective Intervention for the Prevention and Treatment of Depressive Disorders
Current Pharmaceutical Design Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Analysis of Annulated Sea Snake Venom, Hydrophis Cyanocinctus, Using Liquid Chromatography and MALDI-TOF/TOF
Current Proteomics The Medicinal Chemistry of Nitrite as a Source of Nitric Oxide Signaling
Current Topics in Medicinal Chemistry Analgesic Considerations for Liver Transplantation Patients
Current Clinical Pharmacology Cardioprotective Effects and <i>in-silico</i> Antioxidant Mechanism of L-Ergothioneine in Experimental Type-2 Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Epidemiology of Septic Acute Kidney Injury
Current Drug Targets Influence of the Bystander Effect on HSV-tk / GCV Gene Therapy. A Review.
Current Gene Therapy Effect of the Antihypertensive Treatment on the Bone Mineral Density and Osteoporotic Fracture
Current Hypertension Reviews Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Recent Patents on CNS Drug Discovery (Discontinued) Metronomic Therapy for Multi Relapsed/Refractory Lymphoma. A Pilot Study
Current Angiogenesis (Discontinued) COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19
Current Medicinal Chemistry PF-04886847 (an Inhibitor of Plasma Kallikrein) Attenuates Inflammatory Mediators and Activation of Blood Coagulation in Rat Model of Lipopolysaccharide (LPS) - Induced Sepsis
Cardiovascular & Hematological Agents in Medicinal Chemistry